A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
Condition(s) studied
Investigational drug(s) / intervention(s)
LM-364 for injection: Q3W, Intravenous Drip
Tislelizumab: Q3W, Intravenous Drip
Study summary
For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors.
For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.
Eligibility
Primary outcome measure(s)
- Incidence of dose-limiting toxicity (DLT) — 78 weeks
Phase I - Incidence of Treatment-Emergent Adverse Events (AEs) — 78 weeks
Phase I - Incidence of serious adverse events (SAEs) — 78 weeks
Phase I - Temperature (Celsius) — 78 weeks
Phase I - Pulse in BPM(Beat per Minute) — 78 weeks
Phase I - Blood Pressure in mmHg — 78 weeks
Phase I - Weight in Kg — 78 weeks
Phase I - Height in centimeters — 78 weeks
Phase I - Blood Routine examination -> Complete Blood Count — 78 weeks
Phase I - Urine Routine examination ->Urinalysis — 78 weeks
Phase I - Blood Biochemistry test -> Electrolytes and Metabolic Parameters — 78 weeks
Phase I - Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), — 78 weeks
Phase I - Pregnancy test — 78 weeks
Phase I - Thyroid Function Test-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) — 78 weeks
Phase I - Echocardiography- LVEF (Left Ventricular Ejection Fraction) in percentage — 78 weeks
Phase I - 12-lead electrocardiogram (ECG) in HR — 78 weeks
Phase I - 12-lead electrocardiogram (ECG) in RR — 78 weeks
Phase I - 12-lead electrocardiogram (ECG) in QRS — 78 weeks
Phase I - 12-lead electrocardiogram (ECG) in QT — 78 weeks
Phase I - 12-lead electrocardiogram (ECG) in QTcF — 78 weeks
Phase I - ECOG(Eastern Cooperative Oncology Group) score — 78 weeks
Phase I - Objective Response Rate (ORR) — 130 weeks
Phase II
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| Macquarie University | North Ryde | New South Wales | |
| Cancer Care Wollongong Hospital | Wollongong | New South Wales | |
| Icon Cancer Centre South Brisbane | Brisbane | Queensland |
More LaNova Medicines Limited trials in Australia
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07694765 on ClinicalTrials.gov ↗ ← All trials in Australia